The consensus molecular subtypes of colorectal cancer
Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and
drug responses. To resolve inconsistencies among the reported gene expression–based CRC …
drug responses. To resolve inconsistencies among the reported gene expression–based CRC …
Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon
…, MD Bautista, E Díaz-Rubio, J Tabernero… - Revista Española de …, 2012 - Elsevier
Las determinaciones de mutaciones en el gen KRAS en el cáncer colorrectal en España se
han venido realizando de manera sistemática en relativamente pocos centros, o bien se …
han venido realizando de manera sistemática en relativamente pocos centros, o bien se …
[PDF][PDF] Diagnóstico y tratamiento del carcinoma hepatocelular
El carcinoma hepatocelular (CHC) es la neoplasia primaria de hıgado más frecuente. Su
incidencia se ha incrementado mundialmente y datos recientes indican que en Espana …
incidencia se ha incrementado mundialmente y datos recientes indican que en Espana …
The landscape of somatic copy-number alteration across human cancers
…, H Sasaki, JE Tepper, JA Fletcher, J Tabernero… - Nature, 2010 - nature.com
A powerful way to discover key genes with causal roles in oncogenesis is to identify
genomic regions that undergo frequent alteration in human cancers. Here we present high-…
genomic regions that undergo frequent alteration in human cancers. Here we present high-…
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch …
…, A Scriva, T Hickish, J Tabernero… - Journal of Clinical …, 2015 - ascopubs.org
Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin
in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free …
in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free …
Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.
…, M Oliveira, E Felip, E Munoz-Couselo, J Tabernero… - 2018 - ascopubs.org
3032 Background: HPD with ICIs has been recently described as progression disease (PD)
by RECIST with a ≥ two-fold increase in tumor growth rate experimental vs. reference. …
by RECIST with a ≥ two-fold increase in tumor growth rate experimental vs. reference. …
[HTML][HTML] Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
…, N Bahary, RK Ramanathan, J Tabernero… - … England Journal of …, 2013 - Mass Medical Soc
Background In a phase 1–2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine,
substantial clinical activity was noted in patients with advanced pancreatic cancer. We …
substantial clinical activity was noted in patients with advanced pancreatic cancer. We …
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis
…, L Mileshkin, D Sia, R Tothill, J Tabernero… - The Lancet …, 2016 - thelancet.com
Background Cancer of unknown primary ranks in the top ten cancer presentations and has
an extremely poor prognosis. Identification of the primary tumour and development of a …
an extremely poor prognosis. Identification of the primary tumour and development of a …
[PDF][PDF] Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer …
E Van Cutsem, J Tabernero, R Lakomy, H Prenen… - J Clin …, 2012 - researchgate.net
Purpose Treatment for metastatic colorectal cancer (mCRC) commonly involves a
fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and …
fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and …
Phase I dose-escalation study of JNJ-42756493, an oral pan–fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
J Tabernero, R Bahleda, R Dienstmann… - Journal of Clinical …, 2015 - ascopubs.org
Purpose JNJ-42756493 is an orally administered pan-fibroblast growth factor receptor (FGFR)
tyrosine kinase inhibitor. This first-in-human study evaluates the safety, pharmacokinetics, …
tyrosine kinase inhibitor. This first-in-human study evaluates the safety, pharmacokinetics, …